The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Sen. Bernie Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor and Pensions (HELP). Novo Nordisk chief Lars Fruergaard Jørgensen told senators Tuesday that pharmacy benefit managers (PBMs),…
Source link
